title: The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.
abstract: The polypeptide hormone prolactin (PRL) stimulates breast epithelial cell growth, differentiation, and motility through its cognate receptor, PRLr. PRLr is expressed in most breast cancers; however, its exact role remains elusive. Our laboratory previously described a novel mode of PRLr signaling in which Stat5a-mediated transcription is regulated through ligand-induced phosphorylation of the PRLr transactivation domain (TAD). Herein, we used a PRLr transactivation-deficient mutant (PRLrYDmut) to identify novel TAD-specific target genes. Microarray analysis identified 120 PRL-induced genes up-regulated by wild type but not PRLrYDmut. Compared with control, PRLr expression significantly induced expression of approximately 4700 PRL-induced genes, whereas PRLrYDmut ablated induction of all but 19 of these genes. Ingenuity pathway analysis found that the PRLr TAD most profoundly affected networks involving cancer and proliferation. In support of this, PRLrYDmut expression reduced anchorage-dependent and anchorage-independent growth. In addition, pathway analysis identified a link between the PRLr TAD and the estrogen and progesterone receptors (ERα/PR). Although neither ERα nor PR was identified as a PRL target gene, a TAD mutation significantly impaired ERα/PR expression and estrogen responsiveness. TMA analysis revealed a marked increase in nuclear, but not cytoplasmic, PRLr TAD phosphorylation as a function of neoplastic progression. We propose that PRLr TAD phosphorylation contributes to breast cancer pathogenesis, in part through regulation of ERα and PR, and has potential utility as a biomarker in this disease.
authors.affiliation: Women's Cancer Research Program, Robert H. Lurie Comprehensive Cancer Center, and the Department of Pathology, Northwestern University, Chicago, Illinois 60611, USA.
authors.forename: Alyson A
authors.initials: AA
authors.lastname: Fiorillo
authors.forename: Terry R
authors.initials: TR
authors.lastname: Medler
authors.forename: Yvonne B
authors.initials: YB
authors.lastname: Feeney
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Wetz
authors.forename: Kalie L
authors.initials: KL
authors.lastname: Tommerdahl
authors.forename: Charles V
authors.initials: CV
authors.lastname: Clevenger
mesh_terms: D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D018450:Disease Progression; D015536:Down-Regulation / Q000187:drug effects; D047628:Estrogen Receptor alpha / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D052138:Genes, Neoplasm; D006801:Humans; D009154:Mutation; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D010766:Phosphorylation / Q000235:genetics; D011379:Prognosis; D011388:Prolactin / Q000494:pharmacology; D011980:Receptors, Progesterone / Q000096:biosynthesis* / Q000235:genetics; D011981:Receptors, Prolactin / Q000096:biosynthesis / Q000235:genetics*; D046888:Tissue Array Analysis / Q000379:methods; D015533:Transcriptional Activation / Q000235:genetics*; D014407:Tumor Cells, Cultured; D015854:Up-Regulation / Q000187:drug effects / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D009363:Neoplasm Proteins; D011980:Receptors, Progesterone; D011981:Receptors, Prolactin; D011388:Prolactin